Neurotech elevates Mark Davies to Executive Chairman as Phase III program advances
Neurotech International (ASX: NTI) has appointed Mr Mark Davies as Executive Chairman, effective 17 August 2026, transitioning from his current role as Non-Executive Chairman.
The Company framed the move as a deliberate step aligned with its progression into the next stage of development. For investors, it signals a more hands-on chairman as Neurotech approaches its Phase III program, refines its funding strategy, and pursues potential partnering and licensing opportunities.
When big ASX news breaks, our subscribers know first
What the expanded mandate covers
As Executive Chairman, Davies will assume a more active role in the strategic and operational leadership of the Company. His broadened responsibilities span the following areas:
-
Corporate strategy
-
Capital markets and funding initiatives
-
Partnering and licensing activities
-
Investor engagement
-
Governance
-
Strategic oversight of the Company’s clinical and regulatory programs
Two of these areas, funding and partnering/licensing, are precisely what a clinical-stage biopharmaceutical company needs to execute as it enters Phase III. The appointment connects leadership directly to execution capability at a critical juncture in the pipeline.
The engagement terms at a glance
The material terms of Davies’ engagement as Executive Chairman, disclosed in accordance with ASX Listing Rule 3.16.4, are summarised below.
| Term | Detail |
|---|---|
| Position | Executive Chairman |
| Commencement | 17 August 2026 |
| Fixed remuneration | A$25,000 per month (inclusive of statutory superannuation, plus GST where applicable) |
| Short/long term incentives | None |
| Term & notice | No fixed term, ongoing; one month’s written notice by either party |
A fixed-fee, incentive-free arrangement with a one-month notice period represents a lean, flexible structure for a company managing its funding runway.
Why the timing matters — NTI164 and the road to Phase III
To understand why an active chairman matters now, it helps to place Neurotech within its development journey. The Company is a clinical-stage biopharmaceutical developer focused predominantly on paediatric neurological disorders.
Its lead therapy, NTI164, is a proprietary, multi-constituent, GMP-grade standardised oral cannabinoid formulation containing CBDA-rich extracts and select minor cannabinoids. According to the Company, preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation, and upstream biological mechanisms implicated in neurodevelopmental disorders.
Neurotech has reported the following clinical progress to date:
-
Completed a Phase II/III randomised, double-blind, placebo-controlled trial in Autism Spectrum Disorder (ASD), reporting clinically meaningful and statistically significant benefits across a number of clinically-validated measures, alongside excellent safety.
-
Completed and reported statistically significant, clinically meaningful Phase I/II trials in PANDAS/PANS and Rett Syndrome.
-
Received human ethics committee clearance for a Phase III clinical study in ASD.
Beyond Harmony trial site activation at Monash Children’s Hospital marked the transition from ethics clearance to active patient screening, with additional sites expected to open as the multi-centre, 150-patient adaptive study expands.
An Executive Chairman focused on funding and partnering directly supports advancing this Phase III pipeline, tying the leadership change to the Company’s next set of clinical milestones.
What investors should watch next
The appointment signals an increased focus on the Phase III program, funding strategy, and potential partnering and licensing opportunities. Davies’ expanded remit positions the Company to pursue these catalysts more actively as it moves forward.
FDA IND clearance for NTI164, secured in July 2026, established a formal US clinical development pathway that sits alongside the Australian Phase 3 Beyond Harmony trial, reinforcing the dual-jurisdiction regulatory strategy that makes partnering discussions more commercially attractive.
From the announcement
The appointment reflects “the Company’s progression into its next stage of development, with an increased focus on the Phase III program, funding strategy and potential partnering and licensing opportunities.”
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ investors who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.